The increased mortality risk of patients with MetS could be associated with the enhanced expression of ACE2, IL6, and TNF- α adipose tissue secretion and elevated concentration of von Willebrand factor and plasminogen activator inhibitor-163. This evidence concerns the gene IL6 and metabolic syndrome.